<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4699244</article-id><article-id pub-id-type="pmid">26694420</article-id><article-id pub-id-type="doi">10.3390/md13127071</article-id><article-id pub-id-type="publisher-id">marinedrugs-13-07071</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>MytiLec, a Mussel R-Type Lectin, Interacts with Surface Glycan Gb3 on Burkitt&#8217;s Lymphoma Cells to Trigger Apoptosis through Multiple Pathways</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>Imtiaj</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref><xref ref-type="aff" rid="af2-marinedrugs-13-07071">2</xref><xref ref-type="author-notes" rid="fn1-marinedrugs-13-07071">&#8224;</xref></contrib><contrib contrib-type="author"><name><surname>Sugawara</surname><given-names>Shigeki</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-13-07071">3</xref><xref ref-type="author-notes" rid="fn1-marinedrugs-13-07071">&#8224;</xref></contrib><contrib contrib-type="author"><name><surname>Fujii</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-13-07071">4</xref></contrib><contrib contrib-type="author"><name><surname>Koide</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref></contrib><contrib contrib-type="author"><name><surname>Terada</surname><given-names>Daiki</given-names></name><xref ref-type="aff" rid="af5-marinedrugs-13-07071">5</xref></contrib><contrib contrib-type="author"><name><surname>Iimura</surname><given-names>Naoya</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujiwara</surname><given-names>Toshiyuki</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-13-07071">4</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Keisuke G.</given-names></name><xref ref-type="aff" rid="af6-marinedrugs-13-07071">6</xref></contrib><contrib contrib-type="author"><name><surname>Kojima</surname><given-names>Nobuhiko</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref></contrib><contrib contrib-type="author"><name><surname>Rajia</surname><given-names>Sultana</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref><xref ref-type="aff" rid="af7-marinedrugs-13-07071">7</xref></contrib><contrib contrib-type="author"><name><surname>Kawsar</surname><given-names>Sarkar M. A.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref><xref ref-type="aff" rid="af8-marinedrugs-13-07071">8</xref></contrib><contrib contrib-type="author"><name><surname>Kanaly</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref></contrib><contrib contrib-type="author"><name><surname>Uchiyama</surname><given-names>Hideho</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref></contrib><contrib contrib-type="author"><name><surname>Hosono</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-13-07071">3</xref></contrib><contrib contrib-type="author"><name><surname>Ogawa</surname><given-names>Yukiko</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-13-07071">4</xref></contrib><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Hideaki</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-13-07071">4</xref></contrib><contrib contrib-type="author"><name><surname>Hamako</surname><given-names>Jiharu</given-names></name><xref ref-type="aff" rid="af9-marinedrugs-13-07071">9</xref></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>Taei</given-names></name><xref ref-type="aff" rid="af9-marinedrugs-13-07071">9</xref></contrib><contrib contrib-type="author"><name><surname>Ozeki</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-13-07071">1</xref><xref rid="c1-marinedrugs-13-07071" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Trincone</surname><given-names>Antonio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-marinedrugs-13-07071"><label>1</label>Department of Life and Environmental System Science, Graduate School of NanoBio Sciences, Yokohama City University, 22-2 Seto, Kanazawa-ku, Yokohama 236-0027, Japan; <email>hasanimtiaj@yahoo.co.uk</email> (I.H.); <email>yasukoide04@yahoo.co.jp</email> (Y.K.); <email>akht.51.314@gmail.com</email> (N.I); <email>nobuhiko@yokohama-cu.ac.jp</email> (N.K.); <email>rajia_bio@yahoo.com</email> (S.R.); <email>akawsarabe@yahoo.com</email> (S.M.A.K.); <email>kanaly@yokohama-cu.ac.jp</email> (R.A.K.); <email>hideho@yokohama-cu.ac.jp</email> (H.U.)</aff><aff id="af2-marinedrugs-13-07071"><label>2</label>Department of Biochemistry and Molecular Biology, Faculty of Science, University of Rajshahi, Rajshahi-6205, Bangladesh</aff><aff id="af3-marinedrugs-13-07071"><label>3</label>Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan; <email>ssuga@tohoku-pharm.ac.jp</email> (S.S.); <email>mhosono@tohoku-pharm.ac.jp</email> (M.H.)</aff><aff id="af4-marinedrugs-13-07071"><label>4</label>Department of Pharmacy, Faculty of Pharmaceutical Science, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan; <email>yfujii@niu.ac.jp</email> (Y.F.); <email>fujiwara@niu.ac.jp</email> (T.F.) <email>yogawa@niu.ac.jp</email> (Y.O.); <email>fujita@niu.ac.jp</email> (H.F.)</aff><aff id="af5-marinedrugs-13-07071"><label>5</label>Graduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan; <email>daiki.tera@tsurumi.yokohama-cu.ac.jp</email></aff><aff id="af6-marinedrugs-13-07071"><label>6</label>Graduate School of Agricultural Science, Tohoku University, 1-1 Amamiya-machi, Tsutsumidori, Aoba-ku, Sendai 230-0045, Japan; <email>keisuke.takahashi.b3@tohoku.ac.jp</email></aff><aff id="af7-marinedrugs-13-07071"><label>7</label>Department of Natural Science, Varendra University, Rajshahi-6204, Bangladesh</aff><aff id="af8-marinedrugs-13-07071"><label>8</label>Department of Chemistry, Faculty of Sciences, University of Chittagong, Chittagong-4331, Bangladesh</aff><aff id="af9-marinedrugs-13-07071"><label>9</label>Department of Biology, School of Health Sciences, Fujita Health University, Toyoake, Aichi 470-1192, Japan; <email>jhamako@fujita-hu.ac.jp</email> (J.H.); <email>tmatsui@fujita-hu.ac.jp</email> (T.M.)</aff><author-notes><corresp id="c1-marinedrugs-13-07071"><label>*</label>Correspondence: <email>ozeki@yokohama-cu.ac.jp</email>; Tel.: +81-45-787-2221; Fax: +81-45-787-2413</corresp><fn id="fn1-marinedrugs-13-07071"><label>&#8224;</label><p>These two authors contributed equally to the study and should be considered co-first authors.</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>13</volume><issue>12</issue><fpage>7377</fpage><lpage>7389</lpage><history><date date-type="received"><day>01</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>&#169; 2015 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2015</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>MytiLec; a novel lectin isolated from the Mediterranean mussel (<italic>Mytilus galloprovincialis</italic>); shows strong binding affinity to globotriose (Gb3: Gal&#945;1-4Gal&#946;1-4Glc). MytiLec revealed &#946;-trefoil folding as also found in the ricin B-subunit type (R-type) lectin family, although the amino acid sequences were quite different. Classification of R-type lectin family members therefore needs to be based on conformation as well as on primary structure. MytiLec specifically killed Burkitt's lymphoma Ramos cells, which express Gb3. Fluorescein-labeling assay revealed that MytiLec was incorporated inside the cells. MytiLec treatment of Ramos cells resulted in activation of both classical MAPK/ extracellular signal-regulated kinase and extracellular signal-regulated kinase (MEK-ERK) and stress-activated (p38 kinase and JNK) Mitogen-activated protein kinases (MAPK) pathways. In the cells, MytiLec treatment triggered expression of tumor necrosis factor (TNF)-&#945; (a ligand of death receptor-dependent apoptosis) and activation of mitochondria-controlling caspase-9 (initiator caspase) and caspase-3 (activator caspase). Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-&#945; production. Activation of caspase-3 by MytiLec appeared to be regulated by multiple different pathways. Our findings, taken together, indicate that the novel R-type lectin MytiLec initiates programmed cell death of Burkitt&#8217;s lymphoma cells through multiple pathways (MAPK cascade, death receptor signaling; caspase activation) based on interaction of the lectin with Gb3-containing glycosphingolipid-enriched microdomains on the cell surface.</p></abstract><kwd-group><kwd>Burkitt&#8217;s lymphoma cells</kwd><kwd>caspase-9/3</kwd><kwd>globotriose (Gb3)</kwd><kwd>JNK</kwd><kwd><italic>Mytilus galloprovincialis</italic></kwd><kwd>MEK/ERK</kwd><kwd>MytiLec</kwd><kwd>p21: p38 kinase</kwd><kwd>R-type lectin</kwd><kwd>TNF-&#945;</kwd><kwd>&#946;-trefoil</kwd></kwd-group></article-meta></front><body><sec id="sec1-marinedrugs-13-07071"><title>1. Introduction</title><p>During the present decade, genome databases have been established for numerous mollusk species, and are very useful in industrial and ecological studies [<xref rid="B1-marinedrugs-13-07071" ref-type="bibr">1</xref>]. &#8220;MytiBase&#8221; is an impacted EST (expressed sequence tags) database for the Mediterranean mussel, <italic>Mytilus galloprovincialis</italic>, a worldwide species that plays major roles in marine ecosystems and is commercially important [<xref rid="B2-marinedrugs-13-07071" ref-type="bibr">2</xref>,<xref rid="B3-marinedrugs-13-07071" ref-type="bibr">3</xref>]. Recent advances in mussel genomics have elucidated the crucial genes in various physiological processes, and shown that certain signal transduction molecules that regulate innate immunity in mussels have analogues in higher animals [<xref rid="B4-marinedrugs-13-07071" ref-type="bibr">4</xref>,<xref rid="B5-marinedrugs-13-07071" ref-type="bibr">5</xref>,<xref rid="B6-marinedrugs-13-07071" ref-type="bibr">6</xref>]. Recent studies have focused on such genes that are capable of being activated by various environmental pollutants. Progress in this area will have important ecological, economic, and human health implications.</p><p>Mussels have been found to produce several interesting bioactive compounds. A furan fatty acid isolated from the green-lipped mussel (<italic>Perna canaliculus</italic>) suppresses inflammatory processes [<xref rid="B7-marinedrugs-13-07071" ref-type="bibr">7</xref>] and breast cancer cell growth <italic>in vitro</italic> [<xref rid="B8-marinedrugs-13-07071" ref-type="bibr">8</xref>], and is currently undergoing clinical trials [<xref rid="B8-marinedrugs-13-07071" ref-type="bibr">8</xref>,<xref rid="B9-marinedrugs-13-07071" ref-type="bibr">9</xref>]. Macromolecules isolated from mussels or other bivalves are useful in food science and as research tools in life sciences [<xref rid="B10-marinedrugs-13-07071" ref-type="bibr">10</xref>].</p><p>A major focus in glycobiology is the regulation of living systems through molecular interactions between glycans (polysaccharides) and their receptors, which include glycan-binding proteins termed "lectins". Monosaccharides comprising a glycan chain are arranged according to axial or equatorial configuration of hydroxyl groups around each carbon atom. The glycosidic linkages are connections between anomeric carbons of adjacent monosaccharides. Changes in length and branching of glycan chains occur during disease processes, ontogenic development, differentiation, and regeneration [<xref rid="B11-marinedrugs-13-07071" ref-type="bibr">11</xref>]. Changes in somatic cells that lead to cancer or reprogramming are often associated with striking changes in glycan chains of glycoproteins and glycosphingolipids to an immature or ancestral form similar to glycans found in Golgi bodies or lower organisms [<xref rid="B11-marinedrugs-13-07071" ref-type="bibr">11</xref>,<xref rid="B12-marinedrugs-13-07071" ref-type="bibr">12</xref>].</p><p>MytiLec is an &#945;-Gal-binding lectin that we isolated in 2012 from the Mediterranean mussel <italic>Mytilus galloprovincialis</italic> (family Mytilidae). Its primary structure is a 17 kDa polypeptide (149 amino acids, including one Trp and no Cys) containing triple tandem-repeating 50-a.a. subdomains [<xref rid="B13-marinedrugs-13-07071" ref-type="bibr">13</xref>,<xref rid="B14-marinedrugs-13-07071" ref-type="bibr">14</xref>]. The cDNA sequence coding MytiLec has also been deposited in the MytiBase EST library [<xref rid="B15-marinedrugs-13-07071" ref-type="bibr">15</xref>]. Deduced a.a. from cDNA coding a Gal/GalNAc-binding lectin isolated from another mytilid mussel, <italic>Crenomytilus grayanus</italic>, gives similar primary structure [<xref rid="B16-marinedrugs-13-07071" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-13-07071" ref-type="bibr">17</xref>]. We showed (by frontal affinity chromatography) that MytiLec binds specifically to globotriose (Gb3; Gal&#945;1-4Gal&#946;1-4Glc) and is toxic to Burkitt&#8217;s lymphoma cells (which express globotriaosylceramide-containing Gb3 glycan on the cell surface) [<xref rid="B13-marinedrugs-13-07071" ref-type="bibr">13</xref>].</p><p>Nevertheless, the primary structure of MytiLec has been quite novel, its 3-D structure obtained by crystallography analysis of MytiLec identified that the lectin had a &#946;-trefoil folding (PDB entry 3wmu at 1.1 &#197; and PDB entry 3wmv at 1.05 &#197; [<xref rid="B18-marinedrugs-13-07071" ref-type="bibr">18</xref>] that is found in the B-subunit of ricin [<xref rid="B19-marinedrugs-13-07071" ref-type="bibr">19</xref>], a representative plant toxin isolated from castor beans (<italic>Ricinus communis</italic>). Lectins having the &#946;-trefoil folding and similar primary structures with the B-subunit of ricin are included in the &#8220;R-type lectin family&#8221;. In addition to possessing this characteristic folding, MytiLec was a non-covalently bound dimer consisting of two polypeptides having the glycan-binding activity in each sub-domain (Jeremy R.H. Tame, personal communication). Six carbohydrate-binding sites of dimer MytiLec was essential for the cytotoxicity (data not shown) similar to the property of another cytotoxic R-type lectin isolated from mushroom <italic>Clitocybe nebularis</italic> [<xref rid="B20-marinedrugs-13-07071" ref-type="bibr">20</xref>]. Taken together, MytiLec fits in as a new member of the R-type lectin family.</p><p>Some R-type lectins have additional domains as toxic subunits. Pierisin, isolated from <italic>Pieris rapae</italic> (cabbage butterfly), has an ADP-ribosyltransferase domain in the polypeptide and three R-type lectin domains. Pierisin induces apoptosis in HeLa cells by binding to surface Gb3 and Gb4 (GalNAc&#946;1-3Gal&#945;1-4Gal&#946;1-4Glc) glycans [<xref rid="B21-marinedrugs-13-07071" ref-type="bibr">21</xref>]. In addition to the original MytiLec, two MytiLec variants (termed MytiLec2 and MytiLec3) containing a pore-forming aerolysin [<xref rid="B22-marinedrugs-13-07071" ref-type="bibr">22</xref>]-like domain in the polypeptide that creates pores into infectious organisms and kills them through initiation of innate immunity, according to the recently updated MytiBase [<xref rid="B4-marinedrugs-13-07071" ref-type="bibr">4</xref>].</p><p>MytiLec does not have additional functional domains or subunits beside glycan-binding domains, in contrast to other R-type lectins, although it is capable of inducing cytotoxicity. It thus occupies a unique category within the R-type lectin family. The mechanisms whereby MytiLec transmits its signals through cells to activate various signal transduction molecules for induction of cancer cell apoptosis are of great interest. We used experimental cell line, Ramos with high levels of Gb3 expression to study apoptosis-inducing molecules (mitogen-activated protein kinases (MAPK) cascade, mitochondria-controlling caspase, and death receptor signal) activated by MytiLec in Burkitt&#8217;s lymphoma cells.</p></sec><sec id="sec2-marinedrugs-13-07071"><title>2. Results and Discussion</title><sec id="sec2dot1-marinedrugs-13-07071"><title>2.1. Glycan-Binding and Cell Agglutination of Recombinant MytiLec</title><p>MytiLec agglutinated Burkitt&#8217;s lymphoma-derived Ramos cells (high Gb3 expression) [<xref rid="B23-marinedrugs-13-07071" ref-type="bibr">23</xref>] but did not agglutinate K562 erythroleukemia cells (no Gb3 expression). Strong agglutination was observed for Ramos, as revealed by large cell masses (<xref ref-type="fig" rid="marinedrugs-13-07071-f001">Figure 1</xref>).</p><fig id="marinedrugs-13-07071-f001" position="float"><label>Figure 1</label><caption><p>Different cell agglutination activities of MytiLec. MytiLec (0, 10, and 50 &#956;g/mL) was applied to Ramos (5 &#215; 10<sup>5</sup> cells) and K562 (2 &#215; 10<sup>5</sup> cells) cells and observed by phase contrast microscopy.</p></caption><graphic xlink:href="marinedrugs-13-07071-g001"/></fig></sec><sec id="sec2dot2-marinedrugs-13-07071"><title>2.2. Cytotoxic Effects of MytiLec on Burkitt&#8217;s Lymphoma Cell Lines</title><p>Cytotoxic effects of MytiLec administration were evaluated by WST-8 assay rather than trypan blue assay because agglutinated cell masses were not effectively stained by trypan blue reagent. Ramos and K562 cells were cultured for 24 h, treated with MytiLec, and reduction in proportion of living cells was assayed by measuring absorbance at 450 nm. Viability was reduced in comparison with control (nontreated) cells for Ramos treated with 10 &#956;g/mL of MytiLec, indicating a cytotoxic effect. Viability of K562 cells, which do not express Gb3, was unaffected by MytiLec treatment (<xref ref-type="fig" rid="marinedrugs-13-07071-f002">Figure 2</xref>A).</p><fig id="marinedrugs-13-07071-f002" position="float"><label>Figure 2</label><caption><p>Reduction of cell viability by MytiLec. (<bold>A</bold>) Determination of viability by WST-8 assay. Dotted columns: Ramos. White columns: K562. Cells (2 &#215; 10<sup>5</sup> of Ramos; 5 &#215; 10<sup>5</sup> of K562) were incubated with various MytiLec concentrations as shown. Error bars: SE (<italic>n</italic> = 3); (<bold>B</bold>) Annexin V-binding and propidium iodide (PI) incorporation in MytiLec-treated cells. Horizontal axis: binding of FITC-labeled annexin V. Phosphatidylserine externalization and PI incorporation were evaluated by FACS analysis using MEBCYTO apoptosis kit. Ramos (<bold>a</bold>,<bold>c</bold>) and K562 (<bold>b</bold>) cells were treated with MytiLec (<bold>a</bold>,<bold>b</bold>: 20 &#956;g/mL; <bold>c</bold>: 0 &#956;g/mL) for 30 min at 4 &#176;C. Data shown are mean values with error bars = SD of triplicate experiments. Asterisks = significant differences (<italic>p</italic> &lt; 0.05) between treated and control groups.</p></caption><graphic xlink:href="marinedrugs-13-07071-g002"/></fig><fig id="marinedrugs-13-07071-f003" position="float"><label>Figure 3</label><caption><p>Internalization of FITC-conjugated MytiLec into Burkitt&#8217;s lymphoma cells. Incubation time: 0 min (<bold>a</bold>,<bold>b</bold>); and 2 h (<bold>c</bold>&#8211;<bold>f</bold>). Cells are treated with FITC-MytiLec in the presence of 25 mM D-galactose, as negative control (<bold>e</bold>,<bold>f</bold>). Cells were observed by fluorescence (<bold>a</bold>,<bold>c</bold>,<bold>e</bold>; ex 498 nm and em 522 nm) and phase-contrast (<bold>b</bold>,<bold>d</bold>,<bold>f</bold>), respectively. Arrows in c and d indicated shrunken cells. Bars indicated 50 &#956;m.</p></caption><graphic xlink:href="marinedrugs-13-07071-g003"/></fig><p>Fluorescence activated cell sorting (FACS) analysis revealed that MytiLec treatment led to deleterious biological processes such as cell membrane inversion and loss of membrane integrity. Horizontal axes in <xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>B show binding of Fluorescein isothiocyanate (FITC)-labeled annexin V, and vertical axes show incorporation of propidium iodide. Increasing MytiLec concentration was associated with shifting of annexin V-positive and propidium iodate-positive populations into the right and upper portions (respectively) of these histograms. K562 cells were unaffected by MytiLec treatment. The membrane inversion and penetration observed in MytiLec-treated Ramos cells were consistent with results of our previous study on Raji cells, another Burkitt's lymphoma cell line [<xref rid="B13-marinedrugs-13-07071" ref-type="bibr">13</xref>]. These effects on the Ramos cell membrane (<xref ref-type="fig" rid="marinedrugs-13-07071-f002">Figure 2</xref>B) appeared to be associated with the cytotoxic effect of MytiLec (<xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>). MytiLec may increase cell fragility by suppressing biosynthesis of cell surface membrane proteins. The triggering concentration of MytiLec is lower for apoptosis (~10 &#956;g/mL) than for necrosis (&gt;20 &#956;g/mL). These observations may be related to the functions of MytiLec in caspase activation and TNF-&#945; production (<xref ref-type="sec" rid="sec2dot4-marinedrugs-13-07071">Section 2.4</xref>).</p></sec><sec id="sec2dot3-marinedrugs-13-07071"><title>2.3. Internalization of MytiLec into Burkitt&#8217;s Lymphoma Cells</title><p>Internalization of fluorescein-conjugated MytiLec (20 &#956;g/mL) by Burkitt's lymphoma cells was demonstrated by confocal microscopy. Cell surface fluorescence was observed at the beginning (<xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>a) and after 2 h incubation, strong intracellular fluorescence was detected due to the migration of FITC-MytiLec (<xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>c <italic>vs.</italic> d). Such internalization was similar to that observed for TF-antigen-binding BEL lectin [<xref rid="B24-marinedrugs-13-07071" ref-type="bibr">24</xref>], an R-type lectin purified from mushroom. Cells with internalized MytiLec looked shrunken and irregular shaped with a characteristic rough surface (<xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>c,d, arrows). This internalization was totally inhibited by the co-presence of <sc>d</sc>-galactose, a haptenic sugar of the lectin (<xref ref-type="fig" rid="marinedrugs-13-07071-f003">Figure 3</xref>e). It can be assumed that the internalization of MytiLec activated a number of cell signaling pathways (described in following sections) whether inhibition of this internalization by the sugar gives an idea about the mechanism of Gb3-dependent signaling.</p></sec><sec id="sec2dot4-marinedrugs-13-07071"><title>2.4. Activation of MAPK Pathways by MytiLec</title><p>MAPKs play essential roles in cell growth and differentiation, cell cycle, and cell death. We found that MytiLec activates several MAPK pathways in Burkitt&#8217;s lymphoma cells.</p><sec id="sec2dot4dot1-marinedrugs-13-07071"><title>2.4.1. Activation of MEK-ERK Pathway</title><p>In Ramos, MytiLec activated the classical MAPK pathway of MAPK/extracellular signal-regulated kinase (MEK)<sub>1/2</sub> and extracellular signal-regulated kinase (ERK)<sub>1/2</sub> signaling cascade in a dose-dependent manner, as shown by Western-blotting (<xref ref-type="fig" rid="marinedrugs-13-07071-f004">Figure 4</xref>A, P-MEK<sub>1/2</sub><italic>vs.</italic> MEK<sub>1/2</sub> and P-ERK<sub>1/2</sub>
<italic>vs.</italic> ERK<sub>1</sub>). No such phosphorylation occurred in K562 (data not shown). Phosphorylation of the MEK-ERK pathway by MytiLec resulted in expression of the cyclin-dependent kinase (CDK) inhibitors p21 (<xref ref-type="fig" rid="marinedrugs-13-07071-f004">Figure 4</xref> column p21). In contrast, up-regulated levels of CDK6 and cyclinD3 were slightly reduced by MytiLec (<xref ref-type="fig" rid="marinedrugs-13-07071-f004">Figure 4</xref>).</p><fig id="marinedrugs-13-07071-f004" position="float"><label>Figure 4</label><caption><p>Effects of MytiLec treatment on MEK, ERK, and cell cycle-related molecules in Burkitt&#8217;s lymphoma Ramos cells. (<bold>A</bold>) Phosphorylation and expression levels of MEK1/2, ERK1/2 and p21, p27, CDK6 and cyclinD3 were shown, respectively. Cells (4 &#215; 10<sup>5</sup> in each experiment) were treated with various concentrations of MytiLec as shown, and activation levels were evaluated by Western blotting of lysates. Solid and dotted lines indicated increasing and decreasing trends, respectively. GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; (<bold>B</bold>) Relative densitometric quantification of P-MEK/MEK, P-ERK/ERK and p21/GAPDH. Each experiment was repeated three times.</p></caption><graphic xlink:href="marinedrugs-13-07071-g004"/></fig><p>Expression of p21 (which binds to CDK and inhibits its activity) is enhanced by various external stimuli and stress factors, resulting in cell cycle arrest at the G<sub>0/1</sub> phase [<xref rid="B25-marinedrugs-13-07071" ref-type="bibr">25</xref>]. Up-regulation of p21 level by MEK has been documented using specific inhibitors [<xref rid="B26-marinedrugs-13-07071" ref-type="bibr">26</xref>]. The above findings indicate that binding of MytiLec and Gb3 on the cells induced MEK-ERK pathway activation and p21 expression, eventually resulting in cell cycle arrest.</p></sec><sec id="sec2dot4dot2-marinedrugs-13-07071"><title>2.4.2. Phosphorylation of Stress-Activated MAPK Pathways (JNK, p38 Kinase)</title><p>In addition to the classical MAPK pathway (MEK-ERK), MytiLec phosphorylated stress-activated MAPK pathways [c-Jun <italic>N</italic>-terminal kinase (JNK) and p38 kinase] in Ramos (<xref ref-type="fig" rid="marinedrugs-13-07071-f005">Figure 5</xref>, asterisks). Evidently, ERK mediated transduction of the MytiLec/ Gb3 binding signal to JNK and p38 kinase. The MytiLec-generated stimuli were equivalent to signals generated by oxidative stresses [<xref rid="B27-marinedrugs-13-07071" ref-type="bibr">27</xref>]. A recent study indicates that the MEK/ERK pathway itself can activate both JNK and p38 kinase [<xref rid="B28-marinedrugs-13-07071" ref-type="bibr">28</xref>]. Certain mannose-binding proteins inhibited cell proliferation through activation of these pathways [<xref rid="B29-marinedrugs-13-07071" ref-type="bibr">29</xref>,<xref rid="B30-marinedrugs-13-07071" ref-type="bibr">30</xref>]. Stress-activated kinases play roles in tumor suppression, apoptosis, termination of cell differentiation, and autophagy [<xref rid="B31-marinedrugs-13-07071" ref-type="bibr">31</xref>].</p><fig id="marinedrugs-13-07071-f005" position="float"><label>Figure 5</label><caption><p>Phosphorylation of JNK and p38 kinase by MytiLec in Burkitt's lymphoma Ramos. Cells (5 &#215; 10<sup>5</sup>) were treated with (+) or without (&#8722;) 20 &#956;g/mL MytiLec, and phosphorylation was evaluated by Western-blotting of cell lysates. (<bold>A</bold>) P-ERK, P-JNK, and P-p38: phosphorylated forms of ERK, JNK, and p38 kinase, respectively. Asterisks: increased phosphorylation; (<bold>B</bold>) Relative densitometric quantification of P-ERK/ERK, P-JNK/JNK and P-p38/p38. Each experiment was repeated three times.</p></caption><graphic xlink:href="marinedrugs-13-07071-g005"/></fig></sec><sec id="sec2dot4dot3-marinedrugs-13-07071"><title>2.4.3. MytiLec-Induced Phosphorylation of MEK-ERK Pathway Causes Cell Cycle Arrest through p21 Up-Regulation</title><p>Pre-incubation with U0126 (a specific MEK<sub>1/2</sub> inhibitor) significantly reduced MytiLec-induced phosphorylation of ERK<sub>1/2</sub> in Ramos (<xref ref-type="fig" rid="marinedrugs-13-07071-f006">Figure 6</xref>, P-ERK<sub>1/2</sub>
<italic>vs.</italic> ERK<sub>1</sub>). U0126 also reversed MytiLec-induced enhancement of p21 expression (<xref ref-type="fig" rid="marinedrugs-13-07071-f006">Figure 6</xref>, p21, asterisks). U0126 had no effect on expression of MEK or P-MEK (<xref ref-type="fig" rid="marinedrugs-13-07071-f006">Figure 6</xref>, P-MEK<sub>1/2</sub>
<italic>vs.</italic> MEK<sub>1/2</sub>), consistent with the finding that U0126 directly inhibits the downstream pathway under P-MEK [<xref rid="B32-marinedrugs-13-07071" ref-type="bibr">32</xref>].</p><p>In conclusion, MytiLec/Gb3 binding in Ramos promoted both the classical MAPK pathway (MEK-ERK) and stress-activated MAPK pathways (JNK, P38 kinase). MytiLec-induced phosphorylation of the MEK-ERK pathway resulted in up-regulation of p21 expression that might lead to cell cycle arrest.</p><fig id="marinedrugs-13-07071-f006" position="float"><label>Figure 6</label><caption><p>Treatment with MEK inhibitor U0126 reversed up-regulation of p21 expression mediated by MytiLec-induced phosphorylation of MEK-ERK pathway. (<bold>A</bold>) Burkitt's lymphoma Ramos cells (4 &#215; 10<sup>5</sup>) were treated with (+) or without (&#8722;) 20 &#956;M U0126 for 5 h, and then with 20 &#956;g/mL MytiLec. Expression levels of P-MEK<sub>1/2</sub>, P-ERK<sub>1/2</sub>, and p21 were evaluated by Western-blotting. Asterisks: disappearance of signals; (<bold>B</bold>) Relative densitometric quantification of P-MEK, P-ERK and p21 with (U0126/MytiLec) or without (MytiLec) the MEK inhibitor. Each experiment was repeated three times.</p></caption><graphic xlink:href="marinedrugs-13-07071-g006"/></fig></sec></sec><sec id="sec2dot5-marinedrugs-13-07071"><title>2.5. TNF-&#945; Induction and Caspase Activation in Ramos Cells</title><p>MytiLec treatment of Burkitt&#8217;s lymphoma Ramos cells triggered production of tumor necrosis factor (TNF)-&#945; and activation of caspase-9 and caspase-3 (<xref ref-type="fig" rid="marinedrugs-13-07071-f007">Figure 7</xref>A). The up-regulation of TNF-&#945; by MytiLec was inhibited by P-MEK inhibitor U0126 and by caspase-3 inhibitor Zn-DEVD-FMK (<xref ref-type="fig" rid="marinedrugs-13-07071-f007">Figure 7</xref>B). Association of TNF-&#945; induction with caspase-3 activation was consistent with a previous observation by Burguillos <italic>et al.</italic> [<xref rid="B33-marinedrugs-13-07071" ref-type="bibr">33</xref>], and suggests that TNF-&#945; expression is concurrently regulated by the MEK-ERK pathway and caspase-3 activation.</p><fig id="marinedrugs-13-07071-f007" position="float"><label>Figure 7</label><caption><p>Activation by MytiLec of procaspase-3, procaspase-9, and TNF-&#945;. (<bold>A</bold>) Activation of procaspase-3 in Ramos (4 &#215; 10<sup>5</sup> cells) incubated with various concentrations of MytiLec as shown, evaluated by Western blotting; (<bold>B</bold>) Up-regulation of TNF-&#945; by MytiLec, and inhibition of caspase activation and TNF-&#945; expression by P-MEK inhibitor U0126 and caspase-3 inhibitor Zn-DEVD-FMK (DEVD). Ramos (4 &#215; 10<sup>5</sup> cells) were treated with (+) or without (&#8722;) 10 &#956;M U0126 or 10 &#956;M DEVD for 2 h, and then with 20 &#956;g/mL MytiLec. TNF-&#945; expression and caspase-3/-9 activation were evaluated by Western blotting. Solid and dotted lines indicated increasing and decreasing trends of phosphorylation, respectively. Asterisks: disappearance of signals. Each experiment was repeated three times.</p></caption><graphic xlink:href="marinedrugs-13-07071-g007"/></fig><p>To elucidate the caspase activation pathway, U0126 was applied to Ramos prior to MytiLec administration. Neither caspase-9 nor caspase-3 was inhibited by U0126, indicating that MytiLec-induced activation of caspase-9 and -3 in these cells is independent of the MEK-ERK pathway (<xref ref-type="fig" rid="marinedrugs-13-07071-f007">Figure 7</xref>A, MytiLec(+)/U0126(+)).</p><p>Previous studies have demonstrated stimulation via phosphorylation of various signal transduction molecules by lectins isolated from lower organisms. In mouse macrophage cell lines, a recombinant B-subunit of ricin was shown to stimulate signal transduction pathways through production of inducible nitric oxide synthase, TNF-&#945;, and interleukin-6 [<xref rid="B34-marinedrugs-13-07071" ref-type="bibr">34</xref>]. Human TNF-&#945; reduced the phagocytic ability of mussel hemocytes [<xref rid="B35-marinedrugs-13-07071" ref-type="bibr">35</xref>]. The normal endogenous role of MytiLec in <italic>M. galloprovincialis</italic> remains unclear. Genome database analysis suggests that it may function in innate immunity [<xref rid="B4-marinedrugs-13-07071" ref-type="bibr">4</xref>]. Certain signal transduction molecules in <italic>M. galloprovincialis</italic> are also found in vertebrates (including humans) [<xref rid="B5-marinedrugs-13-07071" ref-type="bibr">5</xref>,<xref rid="B36-marinedrugs-13-07071" ref-type="bibr">36</xref>], suggesting similarities in the fundamental regulatory mechanisms of growth, differentiation, and cell proliferation. A role of native MytiLec in supporting innate immunity could explain its cytotoxic activity against Burkitt's lymphoma cells, since the mussel and vertebrate cells may have common surface glycans such as Gb3, as well as similar cell regulatory mechanisms. Along this line, we are attempting to identify the endogenous ligands of Gb3 and related glycans in the mussel. We previously observed binding of MytiLec to endogenous glycans in mussel tissue [<xref rid="B13-marinedrugs-13-07071" ref-type="bibr">13</xref>]. Surface Gb3 expression was observed on cultured cells derived from sea bass (<italic>Dicentrarchus labrax</italic>) [<xref rid="B37-marinedrugs-13-07071" ref-type="bibr">37</xref>].</p><p>There are difficulties in studying marine drugs based on proteins. Proteins trigger immune responses, and present logistical research problems because of their large size. However, recent studies based on each of sialic acid-binding and &#945;-galacotside-binding lectins-coding genes from fish and sea urchin, respectively successfully recombined the genes into an adenovirus vector and applied the lectins for oncotherapy <italic>in vitro</italic> [<xref rid="B38-marinedrugs-13-07071" ref-type="bibr">38</xref>,<xref rid="B39-marinedrugs-13-07071" ref-type="bibr">39</xref>]. MytiLec, with its novel cytotoxic properties, has great potential for similar therapeutic application through Gb3-signaling.</p><p>Ponting <italic>et al.</italic> [<xref rid="B40-marinedrugs-13-07071" ref-type="bibr">40</xref>] reviewed studies since 1990 of &#946;-trefoil folding, including the question of why toxins (ricin B-chain [<xref rid="B19-marinedrugs-13-07071" ref-type="bibr">19</xref>]), cytokines (fibroblast growth factor [<xref rid="B41-marinedrugs-13-07071" ref-type="bibr">41</xref>], interleukin-1 [<xref rid="B42-marinedrugs-13-07071" ref-type="bibr">42</xref>]), enzymes (non-catalytic domain of glycosyltransferases [<xref rid="B43-marinedrugs-13-07071" ref-type="bibr">43</xref>]) and protease inhibitors (Kunitz-type protease inhibitor [<xref rid="B44-marinedrugs-13-07071" ref-type="bibr">44</xref>]) are synchronically assigned to the same 3D structural group even though their primary structures have low similarity (&lt;12%). The polypeptides are highly conserved, with triple-tandem repeating sequences that contain four &#946;-sheets and one &#945;-helix in each subdomain. It appears that &#946;-trefoil folding is one of the most versatile templates for protein conformation, and is involved in a wide range of physiological functions in many organisms. The primary structure of MytiLec is unique in that gene coding for R-type lectins has not been reported for any other <italic>Mytilus</italic> species. We hypothesize that an ancestral gene was synchronically modified for &#946;-trefoil folding in MytiLec in association with its role in innate immunity.</p><p>The cell regulatory properties of Gb3-binding lectins are clearly diverse and merit further study. SAL, a Gb3-specific SUEL/RBL-type lectin isolated from catfish (<italic>Silurus asotus</italic>) eggs, phosphorylated several signal transduction molecules, resulting in cell cycle delay but had no cytotoxic effect [<xref rid="B45-marinedrugs-13-07071" ref-type="bibr">45</xref>], unlike MytiLec. SAL was found to down-regulate the multidrug resistance (MDR) 1 P-glycoprotein (MDR1 P-gp) on Burkitt's lymphoma cells through Gb3 and did not directly influence the viability of the cells. In this study, Gb3 was found to be an effective trigger to regulate cancer cell growth through apoptosis. Therefore, along with Burkitt&#8217;s lymphoma cells, a number of Gb3-expressing cancer cell lines [<xref rid="B46-marinedrugs-13-07071" ref-type="bibr">46</xref>] like HeLa, MCF-7 and T47D, can be good targets to study cell signaling. In particular, detailed investigation of these lectins and their properties will be useful for development of novel anti-cancer drugs and therapeutic strategies.</p></sec></sec><sec id="sec3-marinedrugs-13-07071"><title>3. Experimental Design</title><sec id="sec3dot1-marinedrugs-13-07071"><title>3.1. Preparation of MytiLec</title><p>MytiLec was purified from Mediterranean mussel <italic>M. galloprovincialis</italic> according to our previous report [<xref rid="B13-marinedrugs-13-07071" ref-type="bibr">13</xref>].</p></sec><sec id="sec3dot2-marinedrugs-13-07071"><title>3.2. Cell Lines and Culture</title><p>Burkitt&#8217;s lymphoma Ramos cell line was obtained from American Type Culture Collection (CRL-1596). Erythroleukemia K562 cell line were obtained from the Cell Resource Center of Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). Cells were cultured in RPMI-1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FBS and antibiotic-antimycotic solution (Life Technologies, Carlsbad, CA, USA), and maintained at 37 &#176;C in a 95% air/5% CO<sub>2</sub> atmosphere.</p></sec><sec id="sec3dot3-marinedrugs-13-07071"><title>3.3. Cytotoxicity and Cell Viability Assays</title><p>Cells were maintained in RPMI-1640 supplemented with heat-inactivated FBS (10% <italic>v</italic>/<italic>v</italic>), penicillin (100 IU/mL), and streptomycin (100 &#956;g/mL) at 37 &#176;C in a 95% air/5% CO<sub>2</sub> atmosphere. Cytotoxic activity and cell growth following treatment with various concentrations of SAL (0&#8211;100 &#956;g/mL) were determined using Cell Counting Kit-8 containing WST-8 (Dojindo Laboratories, Kumamoto, Japan) [<xref rid="B47-marinedrugs-13-07071" ref-type="bibr">47</xref>]. To evaluate the inhibitory effects of sugars, sucrose and melibiose (each 200 mM) were co-incubated with SAL (100 &#956;g/mL) for 24 h and applied to the assay system. Cells (5 &#215; 10<sup>4</sup>, in 90 &#181;L solution) were seeded into a 96-well flat-bottom plate and treated with various concentrations of MytiLec (10 &#181;L) for 24 h at 37 &#176;C. The effect of MytiLec on cell growth was assayed by addition of WST-8 solution (10 &#181;L) to each well and incubation for 4 h at 37 &#176;C. The reduction in proportion of living cells was assayed by measurement of absorbance at 450 nm using a GloMax Multi Detection System (Promega, Madison, WI, USA).</p></sec><sec id="sec3dot4-marinedrugs-13-07071"><title>3.4. Fluorescein Isothiocyanate (FITC)-Conjugated MytiLec</title><p>For confocal microscopy, purified MytiLec (2 mg) was chemically conjugated with NH<sub>2</sub>-reactive fluorescein isothioycanate (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer&#8217;s protocol. Burkitt&#8217;s lymphoma cells (100 &#956;L; 2 &#215; 10<sup>5</sup> cells/mL) in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS were seeded onto 18-mm round cover slips in Petri dishes and left to attach overnight at 37 &#176;C in a humidified 5% CO<sub>2</sub> atmosphere. The cover slips were washed three times with 2 mL PBS, incubated for 2 h with 50 &#956;g/mL FITC-labeled lectin in PBS, and washed again. Cells were fixed with 4% paraformaldehyde for 15 min. Images at various focal planes were taken with a Leica TCS PS5 confocal microscope. 498 nm lasers were used for excitation of FITC.</p></sec><sec id="sec3dot5-marinedrugs-13-07071"><title>3.5. Protein Expression of Signal Transduction Molecules and Their Phosphorylated Forms</title><p>Cells (5 &#215; 10<sup>5</sup>) were cultured for 12 or 24 h in RPMI-1640 with or without MytiLec (100 &#181;g/mL) at 37 &#176;C in 95% air/ 5% CO<sub>2</sub>. Cell lysate was prepared using an AllPrep RNA/Protein Kit (Qiagen, Hilden, Germany), subjected to SDS-PAGE (12.5% separation gel), and electrotransferred onto polyvinylidene difluoride (PVDF) membrane (pore size 0.45 &#181;m) (Hybond-P; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to the manufacturer&#8217;s protocol. The membrane was treated with blocking buffer (Blocking One; Nacalai Tesque, Kyoto, Japan) for 1 h at room temperature and washed with Tris-buffered saline (TBS) containing 0.05% Tween-20. The primary antibodies used were directed to p21 Waf1/Cip1 (1:1000, rabbit mAb, clone 12D1; Cell Signaling Technology, Danvers, MA, USA (CST)), p27 Kip1 (1:2000, rabbit mAb; clone D69C12; CST), CDK6 (1:2000, mouse mAb; clone DCS156; CST), cyclin D3 (1:5000, mouse mAb; clone DCS22; CST), phospho-MEK<sub>1/2</sub> (1:5000, rabbit mAb; CST), phospho-ERK<sub>1/2</sub> (1:5000, mouse mAb; BD Biosciences, San Jose, CA, USA), and GAPDH (1:50,000, mouse mAb; clone 6C5; Ambion/ Invitrogen; Carlsbad, CA, USA). These antibodies were applied in immunoreaction enhancer solution (Can Get Signal Solution 1; Toyobo, Osaka, Japan). The membrane was incubated for 16 h at 4 &#176;C. The secondary antibody, horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (Chemicon International, Temecula, CA, USA), was diluted 1:20,000 in immunoreaction enhancer solution. The membrane was incubated for 1 h at room temperature, exposed to X-ray film (Fuji Film, Tokyo, Japan) using enhanced chemical luminescence, and Western blotted with Enhanced chemiluminescence (ECL) Prime detection reagent (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 1,4-Diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) (1 &#181;g) (Calbiochem, San Diego, CA, USA), a synthetic inhibitor of MEK<sub>1/2</sub> [<xref rid="B44-marinedrugs-13-07071" ref-type="bibr">44</xref>], was dissolved in 247 &#181;L DMSO to create 10 mM stock solution. Cells were incubated with U0126 (10 &#181;M) in RPMI-1640 with FBS for 2 h, added with MytiLec (100 &#181;g/mL), and incubated for 12 h. Whole cell extracts were separated by SDS-PAGE on 12.5% gel and blotted onto PVDF membranes. Phosphorylated kinases were identified by western blotting with anti-phospho-MEK<sub>1/2</sub>, anti-MEK<sub>1/2</sub>, anti-phospho-ERK<sub>1/2</sub>, anti-ERK<sub>1</sub>, and HRP-conjugated anti-mouse IgG antibodies. Signals were detected by X-ray film exposure and western blotting as described above.</p></sec><sec id="sec3dot6-marinedrugs-13-07071"><title>3.6. Statistical Analysis</title><p>Data are presented as mean &#177; SE. Differences between means were evaluated by two-tailed Student&#8217;s <italic>t</italic>-test, with <italic>p</italic> &lt; 0.05 considered to be statistically significant.</p></sec></sec><sec id="sec4-marinedrugs-13-07071"><title>4. Conclusions</title><p>We evaluated the mechanism of the cytotoxic effect of MytiLec purified from <italic>Mytilus galloprovincialis</italic> on Burkitt&#8217;s lymphoma Ramos cells. MytiLec triggered activation of various cell death pathways including MAPK cascade (phosphorylation of MEK-ERK, JNK, and p38 kinase pathways), death receptor signal (TNF-&#945; expression), and activation of mitochondria-controlling caspase-9 and caspase-3, through interaction with glycan Gb3 present in glycosphingolipid-enriched microdomains on the cell surface.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported in part by Grants-In-Aid from the Japan Society for the Promotion of Science (JSPS), the Academic Frontier Project for Private Universities, the Strategic Project to Support the Formation of Research Bases at Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), The Science Research Promotion Fund from The Promotion and Mutual Aid Corporation for Private Schools, and Yokohama City University, Japan. The authors are grateful to Prof. Shu-Ichi Matsuzawa, Sanford-Burnham Medical Research Institute (La Jolla, CA, USA) for useful suggestions, and to S. Anderson for English editing of the manuscript.</p></ack><notes><title>Author Contributions</title><p>Imtiaj Hasan and Shigeki Sugawara are considered co-first authors and performed the majority of the research. Imtiaj Hasan and Yasuhiro Ozeki wrote the manuscript. Yasuhiro Koide, Daiki Terada, Yuki Fujii, Naoya Imura, Keisuke G.Takahashi and Sultana Rajia were involved in experimental work and data analysis. Toshiyuki Fujiwara, Hideho Uchiyama and Nobuhiko Kojima provided laboratory support. Sarkar M.A. Kawsar, Robert A. Kanaly, Masahiro Hosono, Yukiko Ogawa, Hideaki Fujita, Jiharu Hamako, and Taei Matsui improved the manuscript through careful review and helpful suggestions.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-13-07071"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su&#225;rez-Ulloa</surname><given-names>V.</given-names></name><name><surname>Fern&#225;ndez-Tajes</surname><given-names>J.</given-names></name><name><surname>Manfrin</surname><given-names>C.</given-names></name><name><surname>Gerdol</surname><given-names>M.</given-names></name><name><surname>Venier</surname><given-names>P.</given-names></name><name><surname>Eir&#237;n-L&#243;pez</surname><given-names>J.</given-names></name></person-group>
<article-title>Bivalve omics: State of the art and potential applications for the biomonitoring of harmful marine compounds</article-title>
<source>Mar. Drugs</source>
<year>2013</year>
<volume>11</volume>
<fpage>4370</fpage>
<lpage>4389</lpage>
<pub-id pub-id-type="doi">10.3390/md11114370</pub-id>
<?supplied-pmid 24189277?><pub-id pub-id-type="pmid">24189277</pub-id></element-citation></ref><ref id="B2-marinedrugs-13-07071"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venier</surname><given-names>P.</given-names></name><name><surname>de Pitt&#224;</surname><given-names>C.</given-names></name><name><surname>Bernante</surname><given-names>F.</given-names></name><name><surname>Varotto</surname><given-names>L.</given-names></name><name><surname>de Nardi</surname><given-names>B.</given-names></name><name><surname>Bovo</surname><given-names>G.</given-names></name><name><surname>Roch</surname><given-names>P.</given-names></name><name><surname>Novoa</surname><given-names>B.</given-names></name><name><surname>Figueras</surname><given-names>A.</given-names></name><name><surname>Pallavicini</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>MytiBase: A knowledgebase of mussel (<italic>M. galloprovincialis</italic>) transcribed sequences</article-title>
<source>BMC Genomics</source>
<year>2009</year>
<volume>10</volume>
<pub-id pub-id-type="doi">10.1186/1471-2164-10-72</pub-id>
<?supplied-pmid 19203376?><pub-id pub-id-type="pmid">19203376</pub-id></element-citation></ref><ref id="B3-marinedrugs-13-07071"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venier</surname><given-names>P.</given-names></name><name><surname>Varotto</surname><given-names>L.</given-names></name><name><surname>Rosani</surname><given-names>U.</given-names></name><name><surname>Millino</surname><given-names>C.</given-names></name><name><surname>Celegato</surname><given-names>B.</given-names></name><name><surname>Bernante</surname><given-names>F.</given-names></name><name><surname>Lanfranchi</surname><given-names>G.</given-names></name><name><surname>Novoa</surname><given-names>B.</given-names></name><name><surname>Roch</surname><given-names>P.</given-names></name><name><surname>Figueras</surname><given-names>A.</given-names></name><name><surname>Pallavicini</surname><given-names>A.</given-names></name></person-group>
<article-title>Insights into the innate immunity of the Mediterranean mussel <italic>Mytilus galloprovincialis</italic></article-title>
<source>BMC Genomics</source>
<year>2011</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.1186/1471-2164-12-69</pub-id>
<?supplied-pmid 21269501?><pub-id pub-id-type="pmid">21269501</pub-id></element-citation></ref><ref id="B4-marinedrugs-13-07071"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerdol</surname><given-names>M.</given-names></name><name><surname>Venier</surname><given-names>P.</given-names></name></person-group>
<article-title>An updated molecular basis for mussel immunity</article-title>
<source>Fish Shellfish Immunol.</source>
<year>2015</year>
<volume>46</volume>
<fpage>17</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">25700785</pub-id></element-citation></ref><ref id="B5-marinedrugs-13-07071"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buchmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Evolution of Innate Immunity: Clues from Invertebrates via Fish to Mammals</article-title>
<source>Front. Immunol.</source>
<year>2014</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00459</pub-id>
<?supplied-pmid 25295041?><pub-id pub-id-type="pmid">25295041</pub-id></element-citation></ref><ref id="B6-marinedrugs-13-07071"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toubiana</surname><given-names>M.</given-names></name><name><surname>Gerdol</surname><given-names>M.</given-names></name><name><surname>Rosani</surname><given-names>U.</given-names></name><name><surname>Pallavicini</surname><given-names>A.</given-names></name><name><surname>Venier</surname><given-names>P.</given-names></name><name><surname>Roch</surname><given-names>P.</given-names></name></person-group>
<article-title>Toll-like receptors and MyD88 adaptors in Mytilus: Complete cds and gene expression levels</article-title>
<source>Dev. Comp. Immunol.</source>
<year>2013</year>
<volume>40</volume>
<fpage>158</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/j.dci.2013.02.006</pub-id>
<?supplied-pmid 23485525?><pub-id pub-id-type="pmid">23485525</pub-id></element-citation></ref><ref id="B7-marinedrugs-13-07071"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakimoto</surname><given-names>T.</given-names></name><name><surname>Kondo</surname><given-names>H.</given-names></name><name><surname>Nii</surname><given-names>H.</given-names></name><name><surname>Kimura</surname><given-names>K.</given-names></name><name><surname>Egami</surname><given-names>Y.</given-names></name><name><surname>Oka</surname><given-names>Y.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Kida</surname><given-names>E.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Akahoshi</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Furan fatty acid as an anti-inflammatory component from the green-lipped mussel <italic>Perna canaliculus</italic></article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2011</year>
<volume>108</volume>
<fpage>17533</fpage>
<lpage>17537</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1110577108</pub-id>
<?supplied-pmid 21972415?><pub-id pub-id-type="pmid">21972415</pub-id></element-citation></ref><ref id="B8-marinedrugs-13-07071"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sukumaran</surname><given-names>S.</given-names></name><name><surname>Pittman</surname><given-names>K.B.</given-names></name><name><surname>Patterson</surname><given-names>W.K.</given-names></name><name><surname>Dickson</surname><given-names>J.</given-names></name><name><surname>Yeend</surname><given-names>S.</given-names></name><name><surname>Townsend</surname><given-names>A.</given-names></name><name><surname>Broadbridge</surname><given-names>V.</given-names></name><name><surname>Price</surname><given-names>T.J.</given-names></name></person-group>
<article-title>A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (<italic>Perna canaliculus</italic>) lipid extract, in patients with advanced prostate and breast cancer</article-title>
<source>Ann. Oncol.</source>
<year>2010</year>
<volume>21</volume>
<fpage>1089</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdp420</pub-id>
<?supplied-pmid 19846468?><pub-id pub-id-type="pmid">19846468</pub-id></element-citation></ref><ref id="B9-marinedrugs-13-07071"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emelyanov</surname><given-names>A.</given-names></name><name><surname>Fedoseev</surname><given-names>G.</given-names></name><name><surname>Krasnoschekova</surname><given-names>O.</given-names></name><name><surname>Abulimity</surname><given-names>A.</given-names></name><name><surname>Trendeleva</surname><given-names>T.</given-names></name><name><surname>Bames</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Treatment of asthma with lipid extract of New Zealand green-lipped mussel: A randomised clinical trial</article-title>
<source>Eur. Respir. J.</source>
<year>2002</year>
<volume>20</volume>
<fpage>596</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1183/09031936.02.02632001</pub-id>
<?supplied-pmid 12358334?><pub-id pub-id-type="pmid">12358334</pub-id></element-citation></ref><ref id="B10-marinedrugs-13-07071"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grienke</surname><given-names>U.</given-names></name><name><surname>Silke</surname><given-names>J.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name></person-group>
<article-title>Bioactive compounds from marine mussels and their effects on human health</article-title>
<source>Food Chem.</source>
<year>2014</year>
<volume>142</volume>
<fpage>48</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.foodchem.2013.07.027</pub-id>
<?supplied-pmid 24001811?><pub-id pub-id-type="pmid">24001811</pub-id></element-citation></ref><ref id="B11-marinedrugs-13-07071"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hasehira</surname><given-names>K.</given-names></name><name><surname>Tateno</surname><given-names>H.</given-names></name><name><surname>Onuma</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name><name><surname>Asashima</surname><given-names>M.</given-names></name><name><surname>Hirabayashi</surname><given-names>J.</given-names></name></person-group>
<article-title>Structural and quantitative evidence for dynamic glycome shift on production of induced pluripotent stem cells</article-title>
<source>Mol. Cell Proteomics</source>
<year>2012</year>
<volume>11</volume>
<fpage>1913</fpage>
<lpage>1923</lpage>
<pub-id pub-id-type="doi">10.1074/mcp.M112.020586</pub-id>
<?supplied-pmid 23023295?><pub-id pub-id-type="pmid">23023295</pub-id></element-citation></ref><ref id="B12-marinedrugs-13-07071"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovbasnjuk</surname><given-names>O.</given-names></name><name><surname>Mourtazina</surname><given-names>R.</given-names></name><name><surname>Baibakov</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Elowsky</surname><given-names>C.</given-names></name><name><surname>Choti</surname><given-names>M.A.</given-names></name><name><surname>Kane</surname><given-names>A.</given-names></name><name><surname>Donowitz</surname><given-names>M.</given-names></name></person-group>
<article-title>The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2005</year>
<volume>102</volume>
<fpage>19087</fpage>
<lpage>19092</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0506474102</pub-id>
<?supplied-pmid 16365318?><pub-id pub-id-type="pmid">16365318</pub-id></element-citation></ref><ref id="B13-marinedrugs-13-07071"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujii</surname><given-names>Y.</given-names></name><name><surname>Dohmae</surname><given-names>N.</given-names></name><name><surname>Takio</surname><given-names>K.</given-names></name><name><surname>Kawsar</surname><given-names>S.M.</given-names></name><name><surname>Matsumoto</surname><given-names>R.</given-names></name><name><surname>Hasan</surname><given-names>I.</given-names></name><name><surname>Koide</surname><given-names>Y.</given-names></name><name><surname>Kanaly</surname><given-names>R.A.</given-names></name><name><surname>Yasumitsu</surname><given-names>H.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><etal/></person-group>
<article-title>A lectin from the mussel <italic>Mytilus galloprovincialis</italic> has a highly novel primary structure and induces glycan-mediated cytotoxicity of globotriaosylceramide-expressing lymphoma cells</article-title>
<source>J. Biol. Chem.</source>
<year>2012</year>
<volume>287</volume>
<fpage>44772</fpage>
<lpage>44783</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.418012</pub-id>
<?supplied-pmid 23093409?><pub-id pub-id-type="pmid">23093409</pub-id></element-citation></ref><ref id="B14-marinedrugs-13-07071"><label>14.</label><element-citation publication-type="webpage">
<article-title>UniProtKB-B3EWR1 (LEC_MYTGA)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.uniprot.org/uniprot/B3EWR1"> www.uniprot.org/uniprot/B3EWR1</ext-link></comment>
<date-in-citation>(accessed on 11 December 2015)</date-in-citation>
</element-citation></ref><ref id="B15-marinedrugs-13-07071"><label>15.</label><element-citation publication-type="gov">
<article-title>Mg_Nor01_51P18 Nor01 Mytilus galloprovincialis cDNA 3-, mRNA sequence</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.ncbi.nlm.nih.gov/nucest/223022238">www.ncbi.nlm.nih.gov/nucest/223022238</ext-link></comment>
<date-in-citation>(accessed on 11 December 2015)</date-in-citation>
</element-citation></ref><ref id="B16-marinedrugs-13-07071"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovalchuk</surname><given-names>S.N.</given-names></name><name><surname>Chikalovets</surname><given-names>I.V.</given-names></name><name><surname>Chernikov</surname><given-names>O.V.</given-names></name><name><surname>Molchanova</surname><given-names>V.I.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Rasskazov</surname><given-names>V.A.</given-names></name><name><surname>Lukyanov</surname><given-names>P.A.</given-names></name></person-group>
<article-title>cDNA cloning and structural characterization of a lectin from the mussel <italic>Crenomytilus grayanus</italic> with a unique amino acid sequence and antibacterial activity</article-title>
<source>Fish Shellfish Immunol.</source>
<year>2013</year>
<volume>35</volume>
<fpage>1320</fpage>
<lpage>1324</lpage>
<pub-id pub-id-type="doi">10.1016/j.fsi.2013.07.011</pub-id>
<?supplied-pmid 23886951?><pub-id pub-id-type="pmid">23886951</pub-id></element-citation></ref><ref id="B17-marinedrugs-13-07071"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belogortseva</surname><given-names>N.I.</given-names></name><name><surname>Molchanova</surname><given-names>V.I.</given-names></name><name><surname>Kurika</surname><given-names>A.V.</given-names></name><name><surname>Skobun</surname><given-names>A.S.</given-names></name><name><surname>Glazkova</surname><given-names>V.E.</given-names></name></person-group>
<article-title>Isolation and characterization of new GalNAc/Gal-specific lectin from the sea mussel <italic>Crenomytilus grayanus</italic></article-title>
<source>Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol.</source>
<year>1998</year>
<volume>119</volume>
<fpage>45</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/S0742-8413(97)00180-1</pub-id>
<pub-id pub-id-type="pmid">9568372</pub-id></element-citation></ref><ref id="B18-marinedrugs-13-07071"><label>18.</label><element-citation publication-type="webpage">
<article-title>PDBe &gt; 3wmv</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/pdbe/entry/pdb/3WMV">http://www.ebi.ac.uk/pdbe/entry/pdb/3WMV</ext-link></comment>
<date-in-citation>(accessed on 11 December 2015)</date-in-citation>
</element-citation></ref><ref id="B19-marinedrugs-13-07071"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rutenber</surname><given-names>E.</given-names></name><name><surname>Robertus</surname><given-names>J.D.</given-names></name></person-group>
<article-title>Structure of ricin B-chain at 2.5 A resolution</article-title>
<source>Proteins</source>
<year>1991</year>
<volume>10</volume>
<fpage>260</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1002/prot.340100310</pub-id>
<?supplied-pmid 1881882?><pub-id pub-id-type="pmid">1881882</pub-id></element-citation></ref><ref id="B20-marinedrugs-13-07071"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pohleven</surname><given-names>J.</given-names></name><name><surname>Renko</surname><given-names>M.</given-names></name><name><surname>Magister</surname><given-names>&#352;.</given-names></name><name><surname>Smith</surname><given-names>D.F.</given-names></name><name><surname>K&#252;nzler</surname><given-names>M.</given-names></name><name><surname>&#352;trukelj</surname><given-names>B.</given-names></name><name><surname>Turk</surname><given-names>D.</given-names></name><name><surname>Kos</surname><given-names>J.</given-names></name><name><surname>Saboti&#232;</surname><given-names>J.</given-names></name></person-group>
<article-title>Bivalent carbohydrate binding is required for biological activity of <italic>Clitocybe nebularis</italic> lectin (CNL), the <italic>N</italic>,<italic>N</italic>&#697;-diacetyllactosediamine (GalNAc&#226;1-4GlcNAc, LacdiNAc)-specific lectin from Basidiomycete <italic>C. nebularis</italic></article-title>
<source>J. Biol. Chem.</source>
<year>2012</year>
<volume>287</volume>
<fpage>10602</fpage>
<lpage>10612</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.317263</pub-id>
<?supplied-pmid 22298779?><pub-id pub-id-type="pmid">22298779</pub-id></element-citation></ref><ref id="B21-marinedrugs-13-07071"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsushima-Hibiya</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Hidari</surname><given-names>K.I.</given-names></name><name><surname>Miyamoto</surname><given-names>D.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Kasama</surname><given-names>T.</given-names></name><name><surname>Kasama</surname><given-names>T.</given-names></name><name><surname>Koyama</surname><given-names>K.</given-names></name><name><surname>Sugimura</surname><given-names>T.</given-names></name><name><surname>Wakabayashi</surname><given-names>K.</given-names></name></person-group>
<article-title>Identification of glycosphingolipid receptors for pierisin-1, a guanine-specific ADP-ribosylating toxin from the cabbage butterfly</article-title>
<source>J. Biol. Chem.</source>
<year>2003</year>
<volume>278</volume>
<fpage>9972</fpage>
<lpage>99728</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M212114200</pub-id>
<?supplied-pmid 12645583?><pub-id pub-id-type="pmid">12645583</pub-id></element-citation></ref><ref id="B22-marinedrugs-13-07071"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>M.W.</given-names></name><name><surname>Buckley</surname><given-names>J.T.</given-names></name><name><surname>Postma</surname><given-names>J.P.</given-names></name><name><surname>Tucker</surname><given-names>A.D.</given-names></name><name><surname>Leonard</surname><given-names>K.</given-names></name><name><surname>Pattus</surname><given-names>F.</given-names></name><name><surname>Tsernoglou</surname><given-names>D.</given-names></name></person-group>
<article-title>Structure of the Aeromonas toxin proaerolysin in its water-soluble and membrane-channel states</article-title>
<source>Nature</source>
<year>1994</year>
<volume>367</volume>
<fpage>292</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1038/367292a0</pub-id>
<?supplied-pmid 7510043?><pub-id pub-id-type="pmid">7510043</pub-id></element-citation></ref><ref id="B23-marinedrugs-13-07071"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mangeney</surname><given-names>M.</given-names></name><name><surname>Lingwood</surname><given-names>C.A.</given-names></name><name><surname>Taga</surname><given-names>S.</given-names></name><name><surname>Caillou</surname><given-names>B.</given-names></name><name><surname>Tursz</surname><given-names>T.</given-names></name><name><surname>Wiels</surname><given-names>J.</given-names></name></person-group>
<article-title>Apoptosis induced in Burkitt&#8217;s lymphoma cells via Gb3/CD77, a glycolipid antigen</article-title>
<source>Cancer Res.</source>
<year>1993</year>
<volume>53</volume>
<fpage>5314</fpage>
<lpage>5319</lpage>
<?supplied-pmid 8221667?><pub-id pub-id-type="pmid">8221667</pub-id></element-citation></ref><ref id="B24-marinedrugs-13-07071"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bovi</surname><given-names>M.</given-names></name><name><surname>Cenci</surname><given-names>L.</given-names></name><name><surname>Perduca</surname><given-names>M.</given-names></name><name><surname>Capaldi</surname><given-names>S.</given-names></name><name><surname>Carrizo</surname><given-names>M.E.</given-names></name><name><surname>Civiero</surname><given-names>L.</given-names></name><name><surname>Chiarelli</surname><given-names>L.R.</given-names></name><name><surname>Galliano</surname><given-names>M.</given-names></name><name><surname>Monaco</surname><given-names>H.L.</given-names></name></person-group>
<article-title>BEL &#946;-trefoil: A novel lectin with antineoplastic properties in king bolete (<italic>Boletus edulis</italic>) mushrooms</article-title>
<source>Glycobiology</source>
<year>2013</year>
<volume>23</volume>
<fpage>578</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="doi">10.1093/glycob/cws164</pub-id>
<?supplied-pmid 23213111?><pub-id pub-id-type="pmid">23213111</pub-id></element-citation></ref><ref id="B25-marinedrugs-13-07071"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>P.P.</given-names></name><name><surname>Danks</surname><given-names>M.K.</given-names></name><name><surname>Kriwacki</surname><given-names>R.W.</given-names></name><name><surname>Harris</surname><given-names>L.C.</given-names></name></person-group>
<article-title>p21<sup>Waf1/Cip1</sup> dysfunction in neuroblastoma: A novel mechanism of attenuating G<sub>0</sub>-G<sub>1</sub> cell cycle arrest</article-title>
<source>Cancer Res.</source>
<year>2003</year>
<volume>63</volume>
<fpage>3840</fpage>
<lpage>3844</lpage>
<?supplied-pmid 12839982?><pub-id pub-id-type="pmid">12839982</pub-id></element-citation></ref><ref id="B26-marinedrugs-13-07071"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J.S.</given-names></name><name><surname>Carter</surname><given-names>S.</given-names></name><name><surname>Reardon</surname><given-names>D.B.</given-names></name><name><surname>Schmidt-Ullrich</surname><given-names>R.</given-names></name><name><surname>Dent</surname><given-names>P.</given-names></name><name><surname>Fisher</surname><given-names>P.B.</given-names></name></person-group>
<article-title>Roles for basal and stimulated p21<sup>Cip-1/WAF1/MDA6</sup> expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells</article-title>
<source>Mol. Biol. Cell</source>
<year>1999</year>
<volume>10</volume>
<fpage>4231</fpage>
<lpage>4246</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.10.12.4231</pub-id>
<?supplied-pmid 10588655?><pub-id pub-id-type="pmid">10588655</pub-id></element-citation></ref><ref id="B27-marinedrugs-13-07071"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klotz</surname><given-names>L.O.</given-names></name><name><surname>Pellieux</surname><given-names>C.</given-names></name><name><surname>Briviba</surname><given-names>K.</given-names></name><name><surname>Pierlot</surname><given-names>C.</given-names></name><name><surname>Aubry</surname><given-names>J.M.</given-names></name><name><surname>Sies</surname><given-names>H.</given-names></name></person-group>
<article-title>Mitogen-activated protein kinase (p38-, JNK-, ERK-) activation pattern induced by extracellular and intracellular singlet oxygen and UVA</article-title>
<source>Eur. J. Biochem.</source>
<year>1999</year>
<volume>260</volume>
<fpage>917</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00255.x</pub-id>
<?supplied-pmid 10103024?><pub-id pub-id-type="pmid">10103024</pub-id></element-citation></ref><ref id="B28-marinedrugs-13-07071"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bavaria</surname><given-names>M.N.</given-names></name><name><surname>Jin</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>R.M.</given-names></name><name><surname>Johnson</surname><given-names>L.R.</given-names></name></person-group>
<article-title>The mechanism by which MEK/ERK regulates JNK and p38 activity in polyamine depleted IEC-6 cells during apoptosis</article-title>
<source>Apoptosis</source>
<year>2014</year>
<volume>19</volume>
<fpage>467</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1007/s10495-013-0944-1</pub-id>
<?supplied-pmid 24253595?><pub-id pub-id-type="pmid">24253595</pub-id></element-citation></ref><ref id="B29-marinedrugs-13-07071"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>A.D.</given-names></name><name><surname>Lei</surname><given-names>Y.M.</given-names></name><name><surname>Shan</surname><given-names>G.Q.</given-names></name><name><surname>Zhang</surname><given-names>L.Y.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.L.</given-names></name></person-group>
<article-title>Mannose-binding lectin inhibits monocyte proliferation through transforming growth factor-&#226;1 and p38 signaling pathways</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<fpage>e72505</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0072505</pub-id>
<?supplied-pmid 24039775?><pub-id pub-id-type="pmid">24039775</pub-id></element-citation></ref><ref id="B30-marinedrugs-13-07071"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamma</surname><given-names>S.M.</given-names></name><name><surname>Kalyanaraman</surname><given-names>V.S.</given-names></name><name><surname>Pahwa</surname><given-names>S.</given-names></name><name><surname>Dominguez</surname><given-names>P.</given-names></name><name><surname>Modesto</surname><given-names>R.R.</given-names></name></person-group>
<article-title>The lectin jacalin induces phosphorylation of ERK and JNK in CD4<sup>+</sup> T cells</article-title>
<source>J. Leukoc. Biol.</source>
<year>2003</year>
<volume>73</volume>
<fpage>682</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.1102534</pub-id>
<?supplied-pmid 12714584?><pub-id pub-id-type="pmid">12714584</pub-id></element-citation></ref><ref id="B31-marinedrugs-13-07071"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sridharan</surname><given-names>S.</given-names></name><name><surname>Jain</surname><given-names>K.</given-names></name><name><surname>Basu</surname><given-names>A.</given-names></name></person-group>
<article-title>Regulation of autophagy by kinases</article-title>
<source>Cancers (Basel)</source>
<year>2011</year>
<volume>3</volume>
<fpage>2630</fpage>
<lpage>2654</lpage>
<pub-id pub-id-type="doi">10.3390/cancers3022630</pub-id>
<?supplied-pmid 24212825?><pub-id pub-id-type="pmid">24212825</pub-id></element-citation></ref><ref id="B32-marinedrugs-13-07071"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Favata</surname><given-names>M.F.</given-names></name><name><surname>Horiuchi</surname><given-names>K.Y.</given-names></name><name><surname>Manos</surname><given-names>E.J.</given-names></name><name><surname>Daulerio</surname><given-names>A.J.</given-names></name><name><surname>Stradley</surname><given-names>D.A.</given-names></name><name><surname>Feeser</surname><given-names>W.S.</given-names></name><name><surname>van Dyk</surname><given-names>D.E.</given-names></name><name><surname>Pitts</surname><given-names>W.J.</given-names></name><name><surname>Earl</surname><given-names>R.A.</given-names></name><name><surname>Hobbs</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Identification of a novel inhibitor of mitogen-activated protein kinase kinase</article-title>
<source>J. Biol. Chem.</source>
<year>1998</year>
<volume>273</volume>
<fpage>18623</fpage>
<lpage>18632</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.273.29.18623</pub-id>
<?supplied-pmid 9660836?><pub-id pub-id-type="pmid">9660836</pub-id></element-citation></ref><ref id="B33-marinedrugs-13-07071"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burguillos</surname><given-names>M.A.</given-names></name><name><surname>Deierborg</surname><given-names>T.</given-names></name><name><surname>Kavanagh</surname><given-names>E.</given-names></name><name><surname>Persson</surname><given-names>A.</given-names></name><name><surname>Hajji</surname><given-names>N.</given-names></name><name><surname>Garcia-Quintanilla</surname><given-names>A.</given-names></name><name><surname>Cano</surname><given-names>J.</given-names></name><name><surname>Brundin</surname><given-names>P.</given-names></name><name><surname>Englund</surname><given-names>E.</given-names></name><name><surname>Venero</surname><given-names>J.L.</given-names></name><etal/></person-group>
<article-title>Caspase signalling controls microglia activation and neurotoxicity</article-title>
<source>Nature</source>
<year>2011</year>
<volume>472</volume>
<fpage>319</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1038/nature09788</pub-id>
<?supplied-pmid 21389984?><pub-id pub-id-type="pmid">21389984</pub-id></element-citation></ref><ref id="B34-marinedrugs-13-07071"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name></person-group>
<article-title>Activation of RAW264.7 mouse macrophage cells <italic>in vitro</italic> through treatment with recombinant ricin toxin-binding subunit B: Involvement of protein tyrosine, NF-&#234;B and JAK-STAT kinase signaling pathways</article-title>
<source>Int. J. Mol. Med.</source>
<year>2013</year>
<volume>32</volume>
<fpage>729</fpage>
<lpage>735</lpage>
<?supplied-pmid 23820591?><pub-id pub-id-type="pmid">23820591</pub-id></element-citation></ref><ref id="B35-marinedrugs-13-07071"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Betti</surname><given-names>M.</given-names></name><name><surname>Ciacci</surname><given-names>C.</given-names></name><name><surname>Lorusso</surname><given-names>L.C.</given-names></name><name><surname>Canonico</surname><given-names>B.</given-names></name><name><surname>Falcioni</surname><given-names>T.</given-names></name><name><surname>Gallo</surname><given-names>G.</given-names></name><name><surname>Canesi</surname><given-names>L.</given-names></name></person-group>
<article-title>Effects of tumour necrosis factor &#225; (TNF&#225;) on Mytilus haemocytes: Role of stress-activated mitogen-activated protein kinases (MAPKs)</article-title>
<source>Biol. Cell</source>
<year>2006</year>
<volume>98</volume>
<fpage>233</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1042/BC20050049</pub-id>
<?supplied-pmid 16060858?><pub-id pub-id-type="pmid">16060858</pub-id></element-citation></ref><ref id="B36-marinedrugs-13-07071"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toubiana</surname><given-names>M.</given-names></name><name><surname>Rosani</surname><given-names>U.</given-names></name><name><surname>Giambelluca</surname><given-names>S.</given-names></name><name><surname>Cammarata</surname><given-names>M.</given-names></name><name><surname>Gerdol</surname><given-names>M.</given-names></name><name><surname>Pallavicini</surname><given-names>A.</given-names></name><name><surname>Venier</surname><given-names>P.</given-names></name><name><surname>Roch</surname><given-names>P.</given-names></name></person-group>
<article-title>Toll signal transduction pathway in bivalves: Complete cds of intermediate elements and related gene transcription levels in hemocytes of immune stimulated <italic>Mytilus galloprovincialis</italic></article-title>
<source>Dev. Comp. Immunol.</source>
<year>2014</year>
<volume>45</volume>
<fpage>300</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.dci.2014.03.021</pub-id>
<?supplied-pmid 24709052?><pub-id pub-id-type="pmid">24709052</pub-id></element-citation></ref><ref id="B37-marinedrugs-13-07071"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y.</given-names></name><name><surname>Tateno</surname><given-names>H.</given-names></name><name><surname>Nakamura-Tsuruta</surname><given-names>S.</given-names></name><name><surname>Kominami</surname><given-names>J.</given-names></name><name><surname>Hirabayashi</surname><given-names>J.</given-names></name><name><surname>Nakamura</surname><given-names>O.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Kamiya</surname><given-names>H.</given-names></name><name><surname>Naganuma</surname><given-names>T.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>The function of rhamnose-binding lectin in innate immunity by restricted binding to Gb3</article-title>
<source>Dev. Comp. Immunol.</source>
<year>2009</year>
<volume>33</volume>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.dci.2008.08.008</pub-id>
<?supplied-pmid 18809432?><pub-id pub-id-type="pmid">18809432</pub-id></element-citation></ref><ref id="B38-marinedrugs-13-07071"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Duan</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group>
<article-title>Exogenous expression of marine lectins DIFBL and SpRBL induces cancer cell apoptosis possibly through PRMT5-E2F-1 pathway</article-title>
<source>Sci. Rep.</source>
<year>2014</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1038/srep04505</pub-id>
</element-citation></ref><ref id="B39-marinedrugs-13-07071"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group>
<article-title>Adenovirus carrying gene encoding <italic>Haliotis disus discus</italic> sialic acid binding lectin induces cancer cell apoptosis</article-title>
<source>Mar. Drugs</source>
<year>2014</year>
<volume>12</volume>
<fpage>3992</fpage>
<lpage>4004</lpage>
<pub-id pub-id-type="doi">10.3390/md12073994</pub-id>
<?supplied-pmid 24983642?><pub-id pub-id-type="pmid">24983642</pub-id></element-citation></ref><ref id="B40-marinedrugs-13-07071"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponting</surname><given-names>C.P.</given-names></name><name><surname>Russell</surname><given-names>R.B.</given-names></name></person-group>
<article-title>Identification of distant homologues of fibroblast growth factors suggests a common ancestor for all &#946;-trefoil proteins</article-title>
<source>J. Mol. Biol.</source>
<year>2000</year>
<volume>302</volume>
<fpage>1041</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1006/jmbi.2000.4087</pub-id>
<?supplied-pmid 11183773?><pub-id pub-id-type="pmid">11183773</pub-id></element-citation></ref><ref id="B41-marinedrugs-13-07071"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>A.E.</given-names></name><name><surname>Cousens</surname><given-names>L.S.</given-names></name><name><surname>Weaver</surname><given-names>L.H.</given-names></name><name><surname>Matthews</surname><given-names>B.W.</given-names></name></person-group>
<article-title>Three-dimensional structure of human basic fibroblast growth factor</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1991</year>
<volume>88</volume>
<fpage>3441</fpage>
<lpage>3445</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.88.8.3441</pub-id>
<?supplied-pmid 1707542?><pub-id pub-id-type="pmid">1707542</pub-id></element-citation></ref><ref id="B42-marinedrugs-13-07071"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veerapandian</surname><given-names>B.</given-names></name></person-group>
<article-title>Structure and function of interleukin-1, based on crystallographic and modeling studies</article-title>
<source>Biophys. J.</source>
<year>1992</year>
<volume>62</volume>
<fpage>112</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3495(92)81796-4</pub-id>
<pub-id pub-id-type="pmid">1534698</pub-id></element-citation></ref><ref id="B43-marinedrugs-13-07071"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fritz</surname><given-names>T.A.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name><name><surname>Trinh</surname><given-names>L.B.</given-names></name><name><surname>Shiloach</surname><given-names>J.</given-names></name><name><surname>Tabak</surname><given-names>L.A.</given-names></name></person-group>
<article-title>The beginnings of mucin biosynthesis: The crystal structure of UDP-GalNAc: Polypeptide &#225;-<italic>N</italic>-acetylgalactosaminyltransferase-T1</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2004</year>
<volume>101</volume>
<fpage>15307</fpage>
<lpage>15312</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0405657101</pub-id>
<?supplied-pmid 15486088?><pub-id pub-id-type="pmid">15486088</pub-id></element-citation></ref><ref id="B44-marinedrugs-13-07071"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ravichandran</surname><given-names>S.</given-names></name><name><surname>Sen</surname><given-names>U.</given-names></name><name><surname>Chakrabarti</surname><given-names>C.</given-names></name><name><surname>Dattagupta</surname><given-names>J.K.</given-names></name></person-group>
<article-title>Cryocrystallography of a Kunitz-type serine protease inhibitor: The 90 K structure of winged bean chymotrypsin inhibitor (WCI) at 2.13 &#506; resolution</article-title>
<source>Acta Crystallogr. D Biol. Crystallogr.</source>
<year>1999</year>
<volume>55</volume>
<fpage>1814</fpage>
<lpage>1821</lpage>
<pub-id pub-id-type="doi">10.1107/S0907444999009877</pub-id>
<?supplied-pmid 10531477?><pub-id pub-id-type="pmid">10531477</pub-id></element-citation></ref><ref id="B45-marinedrugs-13-07071"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>S.</given-names></name><name><surname>Hosono</surname><given-names>M.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Takayanagi</surname><given-names>M.</given-names></name><name><surname>Nitta</surname><given-names>K.</given-names></name></person-group>
<article-title>Catfish egg lectin causes rapid activation of multidrug resistance 1 P-glycoprotein as a lipid translocase</article-title>
<source>Biol. Pharm. Bull.</source>
<year>2005</year>
<volume>28</volume>
<fpage>434</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1248/bpb.28.434</pub-id>
<?supplied-pmid 15744065?><pub-id pub-id-type="pmid">15744065</pub-id></element-citation></ref><ref id="B46-marinedrugs-13-07071"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johansson</surname><given-names>D.</given-names></name><name><surname>Kosovac</surname><given-names>E.</given-names></name><name><surname>Moharer</surname><given-names>J.</given-names></name><name><surname>Ljuslinder</surname><given-names>I.</given-names></name><name><surname>Br&#228;nnstr&#246;m</surname><given-names>T.</given-names></name><name><surname>Johansson</surname><given-names>A.</given-names></name><name><surname>Behnam-Motlagh</surname><given-names>P.</given-names></name></person-group>
<article-title>Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis</article-title>
<source>BMC Cancer</source>
<year>2009</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.1186/1471-2407-9-67</pub-id>
<?supplied-pmid 19245689?><pub-id pub-id-type="pmid">19245689</pub-id></element-citation></ref><ref id="B47-marinedrugs-13-07071"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawano</surname><given-names>T.</given-names></name><name><surname>Sugawara</surname><given-names>S.</given-names></name><name><surname>Hosono</surname><given-names>M.</given-names></name><name><surname>Tatsuta</surname><given-names>T.</given-names></name><name><surname>Nitta</surname><given-names>K.</given-names></name></person-group>
<article-title>Alteration of gene expression induced by <italic>Silurus asotus</italic> lectin in Burkitt's lymphoma cells</article-title>
<source>Biol. Pharm. Bull.</source>
<year>2008</year>
<volume>31</volume>
<fpage>998</fpage>
<lpage>1002</lpage>
<pub-id pub-id-type="doi">10.1248/bpb.31.998</pub-id>
<?supplied-pmid 18451534?><pub-id pub-id-type="pmid">18451534</pub-id></element-citation></ref></ref-list></back></article>